|View printer-friendly version|
|NeuroDerm to Host Investor Day on April 21, 2017|
Members of NeuroDerm’s executive team will be joined by key opinion leaders to review the company’s clinical programs for treating patients with moderate and severe Parkinson’s disease addressing deficiencies of current treatments, to discuss continuous levodopa administration and its potential to delay motor complications and present the company's future development plans.
Individuals can access the webcast in the Events and Presentations section of the Investor Relations page at NeuroDerm.com. The webcast will be archived on the website.
Analysts and institutional investors seeking more information about this event should contact
U.S. Investor Contact: